|
Nephronophthisis
|
0.200 |
Biomarker
|
disease |
MGD |
|
|
|
|
Rheumatoid Arthritis
|
0.090 |
GeneticVariation
|
disease |
BEFREE |
Data from North European rheumatoid arthritis (RA) populations has suggested a particularly strong association of gene-environment interaction between smoking and HLA-DRB1 shared epitope (SE) with antibodies to citrullinated α-enolase (CEP-1) and vimentin (cVim) peptides.
|
23505239 |
2014 |
|
Rheumatoid Arthritis
|
0.090 |
Biomarker
|
disease |
BEFREE |
Increased anti-CEP-1 antibody titers were detected in nine out of the 15 (60%) ACPA+ pSS patients and 5 out of 12 (41.7%) ACPA+ RA patients; no reactivities were detected in ACPA- pSS patients and HC.
|
28919520 |
2017 |
|
Rheumatoid Arthritis
|
0.090 |
Biomarker
|
disease |
BEFREE |
The fact that arthritis and anti-CEP-1 antibodies were induced independent of citrullination of the immunizing antigen suggests that the unmodified form of α-enolase may be important in initiating the corresponding subset of human RA.
|
21953289 |
2011 |
|
Rheumatoid Arthritis
|
0.090 |
Biomarker
|
disease |
BEFREE |
A-CEP-1 were positive in 77% of RF(+) RA patients, in 56% of RF(-) RA patients, in 8.7% of UA patients, but they were negative in controls.
|
30406565 |
2019 |
|
Rheumatoid Arthritis
|
0.090 |
Biomarker
|
disease |
BEFREE |
Anti-CEP-1 and anti-CCP antibodies were observed in 26.8% and 71.2% of the patients with RA, respectively.
|
21360494 |
2011 |
|
Rheumatoid Arthritis
|
0.090 |
Biomarker
|
disease |
BEFREE |
Our findings indicate that anti-CEP-1 may not be able to replace anti-CCP2 for routine diagnosis for RA, but they may be helpful for subtyping of the disease.
|
30611755 |
2019 |
|
Rheumatoid Arthritis
|
0.090 |
Biomarker
|
disease |
BEFREE |
Anti-CEP-1 antibodies are detectable in over 40% of RA patients and are associated with erosive RA and with RA-associated interstitial lung disease (ILD).
|
29452423 |
2018 |
|
Rheumatoid Arthritis
|
0.090 |
Biomarker
|
disease |
BEFREE |
Levels of antibodies to CEP-1, cFIBβ, and cVIM correlated with each other, and with smoking and shared epitope risk factors in RA.
|
29084415 |
2017 |
|
Rheumatoid Arthritis
|
0.090 |
Biomarker
|
disease |
BEFREE |
Altogether, 44·2, 86·1 and 13·9% of RA sera were positive for anti-CEP-1, -CCP and -GPI protein antibodies, respectively.
|
23480184 |
2013 |
|
Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement
|
0.050 |
GeneticVariation
|
disease |
BEFREE |
To date, four gene fusions associated with distinct translocations have been described in EMS: the t(8;13)(p11;q12), t(8;9)(p11;q33), t(6;8)(q27;p11) and t(8;22)(p11q22) fuse ZNF198, CEP110, FOP and BCR, respectively, to FGFR1.
|
11919391 |
2002 |
|
Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement
|
0.050 |
GeneticVariation
|
disease |
BEFREE |
We report a rare case of t(8;9)(p11;q33) in a patient with 8p11 myeloproliferative syndrome (EMS) that was preceded by centrosomal protein 110kDa (CEP110; previously CEP1)/fibroblast growth factor receptor 1 (FGFR1) fusion transcript.
|
18295660 |
2008 |
|
Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement
|
0.050 |
Biomarker
|
disease |
BEFREE |
Screening of drugs to treat 8p11 myeloproliferative syndrome using patient-derived induced pluripotent stem cells with fusion gene CEP110-FGFR1.
|
25803811 |
2015 |
|
Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement
|
0.050 |
GeneticVariation
|
disease |
BEFREE |
The 8p11 myeloproliferative syndrome (EMS) is associated with three translocations, t(8;13)(p11;q12), t(8;9)(p11;q33), and t(6;8)(q27;p11), that fuse unrelated genes (ZNF198, CEP110, and FOP, respectively) to the entire tyrosine kinase domain of FGFR1.
|
11550283 |
2001 |
|
Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement
|
0.050 |
Biomarker
|
disease |
BEFREE |
A biphenotypic transformation of 8p11 myeloproliferative syndrome with CEP1/FGFR1 fusion gene.
|
16879608 |
2006 |
|
Refractory anemias
|
0.020 |
Biomarker
|
disease |
BEFREE |
A-CEP-1 were positive in 77% of RF(+) RA patients, in 56% of RF(-) RA patients, in 8.7% of UA patients, but they were negative in controls.
|
30406565 |
2019 |
|
Refractory anemias
|
0.020 |
Biomarker
|
disease |
BEFREE |
Anti-CEP-1 antibodies are detectable in over 40% of RA patients and are associated with erosive RA and with RA-associated interstitial lung disease (ILD).
|
29452423 |
2018 |
|
Chronic myeloproliferative disorder
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
FGFR1 is fused to the centrosome-associated protein CEP110 in the 8p12 stem cell myeloproliferative disorder with t(8;9)(p12;q33).
|
10688839 |
2000 |
|
Chronic myeloproliferative disorder
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
NIN, a gene encoding a CEP110-like centrosomal protein, is fused to PDGFRB in a patient with a t(5;14)(q33;q24) and an imatinib-responsive myeloproliferative disorder.
|
15087377 |
2004 |
|
Arthritis
|
0.010 |
Biomarker
|
disease |
BEFREE |
The fact that arthritis and anti-CEP-1 antibodies were induced independent of citrullination of the immunizing antigen suggests that the unmodified form of α-enolase may be important in initiating the corresponding subset of human RA.
|
21953289 |
2011 |
|
Eosinophilia
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
8p11 myeloproliferative syndrome preceded by t(8;9)(p11;q33), CEP110/FGFR1 fusion transcript: morphologic, molecular, and cytogenetic characterization of myeloid neoplasms associated with eosinophilia and FGFR1 abnormality.
|
18295660 |
2008 |
|
leukemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Targeted therapy and disease monitoring in CNTRL-FGFR1-driven leukaemia.
|
31250523 |
2019 |
|
melanoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
The results of our study suggest that FAN through promoting melanoma cellular motility and tumour invasiveness is critical for the tumour-promoting action of TNF.
|
23674089 |
2013 |
|
Degenerative polyarthritis
|
0.010 |
Biomarker
|
disease |
BEFREE |
ACPAs of CK13 (cCK13), tenascin-C (cTNC5), vimentin (cVIM), α-enolase (CEP-1), and fibrinogen β (cFIBβ) were examined by enzyme-linked immunosorbent assay in patients with RA (n = 287) and patients with osteoarthritis (n = 330), and cross-reactivity was assessed by inhibition assays.
|
29084415 |
2017 |
|
Systemic Scleroderma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Our aim is to determine the prevalence of anti-CEP-1 in a cohort of ACPA positive (ACPA+) primary Sjogren's syndrome (pSS) patients.
|
28919520 |
2017 |